Human cells express up to seven different DNA cytosine deaminases, APOBEC3(A3)A-H, which have overlapping functions in innate antiviral immunity. Several A3s, most notably A3G, have been well characterized in inhibiting HIV-1 replication by converting C-to-U in retroviral single-stranded cDNA replication intermediates, thereby generating hypermutated viral genomes. To overcome A3-mediated restriction, viruses have evolved counteraction measures such as the lentiviral Vif protein, which nucleates the formation of a ubiquitin ligase complex that degrades A3 enzymes. We hypothesize that, like HIV-1 and related lentiviruses, herpesviruses including Epstein-Barr virus (EBV) possess mechanisms to counteract restriction by A3 enzymes.
The EBV ribonucleotide reductase subunit BORF2 was used in proteomic experiments to identify cellular binding partners. Interactions were confirmed using co-IP and mutagenesis experiments. Recombinant proteins were used in DNA C-to-U assays. Immunofluorescence and live cell imaging were used to address subcellular localization. CRISPR was used to generate BORF2-null EBV, and Sanger and next-generation sequencing were used to quantify viral genome integrity during lytic reactivation.
The BORF2-APOBEC3B (A3B) interaction was discovered in a proteomic screen and validated by immunoprecipitation experiments and binding assays with recombinant proteins. Structure-guided mutagenesis experiments map the interaction to a conserved loop in the A3B catalytic domain, and biochemical studies demonstrate stoichiometric inhibition of A3B DNA cytosine deaminase activity by BORF2. Fluorescence and electron microscopy images, including movies of full cell division cycles, reveal a dramatic BORF2-dependent re-localization of nuclear A3B to perinuclear foci that may be residual bodies. CRISPR/Cas9-mediated deletion of BORF2 renders EBV susceptible to hypermutation by A3B.
The large double-stranded DNA herpesvirus EBV uses the large subunit of its ribonucleotide reductase, BORF2, to counteract A3B-mediated restriction/mutagenesis in a two-pronged approach through direct enzymatic inhibition and cellular relocalization. This mechanism is distinct from the proteasomal degradation mechanism used by lentiviruses and suggests new avenues for intervention.